Grants per year
Personal profile
Research Interests
Dr. VanderWeele did his medical and research training at the University of Chicago, where he developed a research program characterizing the heterogeneity and evolution of the cancer genome. He moved to the National Cancer Institute in Bethesda, MD, where he continued to seek to improve the treatment of prostate cancer based on patients’ specific genetic changes. He returned to Chicago in 2018 to join the GU cancer team at Northwestern University, where he continues to translate discoveries made at the bench into improved therapies in the clinic.
Training Experience
| 2009 | Residency, University of Chicago |
| 2013 | Fellowship, University of Chicago |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, MD, University of Chicago
… → 2007
Cancer Biology, PhD, University of Chicago
… → 2005
Research interests keywords
- Bladder Cancer
- Kidney Cancer / Urinary Tract Cancer
- Oncology
- Prostate Cancer
Fingerprint
Dive into the research topics where David James VanderWeele is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #NKT2152-202: A Phase 2 Trial to Evaluate the Safety and Efficacy of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in Subjects with Advanced or Metastatic Clear Cell Renal Cell Carcinoma
VanderWeele, D. J. (PD/PI)
Pharmaceutical Research Associates, Inc., NiKang Therapeutics, Inc.
11/1/23 → 11/1/26
Project: Research project
-
Prot #CURLu177PSM0001: A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
VanderWeele, D. J. (PD/PI)
Cato Research Ltd., Curium US LLC
1/26/23 → 1/26/26
Project: Research project
-
Prot #CAAA617C12301: PSMAddition: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard of Care, Versus Standard of Care Alone, in Adult Male Patients with Metastatic Hormone Sensitive P
VanderWeele, D. J. (PD/PI)
Novartis Pharmaceuticals Corporation
2/9/22 → 11/21/25
Project: Research project
-
SPORE in Prostate Cancer
Abdulkadir, S. A. (PD/PI), Abdulkadir, S. A. (PD/PI), Hussain, M. (Co-PD/PI), Hussain, M. (Co-PD/PI), Catalona, W. J. (Co-Investigator), Catalona, W. J. (Co-Investigator), Chakravarti, D. (Co-Investigator), Chakravarti, D. (Co-Investigator), Cooper, L. A. D. (Co-Investigator), Kim, K.-Y. A. (Co-Investigator), Kim, K.-Y. A. (Co-Investigator), Kim, K.-Y. A. (Co-Investigator), Morgans, A. K. (Co-Investigator), Morgans, A. K. (Co-Investigator), Murphy, A. B. (Co-Investigator), Murphy, A. B. (Co-Investigator), Ross, A. E. (Co-Investigator), Schiltz, G. E. (Co-Investigator), Schiltz, G. E. (Co-Investigator), VanderWeele, D. J. (Co-Investigator), Wei, J.-J. (Co-Investigator), Wei, J.-J. (Co-Investigator), Yang, R. (Co-Investigator), Yang, R. (Co-Investigator), Yu, J. (Co-Investigator), Yu, J. (Co-Investigator), Kocherginsky, M. (Other), Kocherginsky, M. (Other), Leikin, R. G. (Other), Leikin, R. G. (Other), Sosman, J. A. (Other), Sosman, J. A. (Other), Wu, J. D. (Other), Wu, J. D. (Other), Yang, X. J. (Other), Yang, X. J. (Other), Yang, R. (Other), Zhao, C. (Other) & Zhao, C. (Other)
9/1/21 → 7/31/26
Project: Research project
-
Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small
Serritella, A. V., Beltran, H., Lotan, T. L., VanderWeele, D. J., Karzai, F., Madan, R. A. & Hussain, M., Mar 2024, In: Oncologist. 29, 3, p. 185-189 5 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report
Ali, S. T. & VanderWeele, D. J., Jul 2024, In: Current Oncology. 31, 7, p. 4015-4021 7 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
Fenton, S. E. & VanderWeele, D. J., Jan 4 2023, In: Frontiers in Oncology. 12, 1069356.Research output: Contribution to journal › Review article › peer-review
Open Access6 Scopus citations -
Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity with Unclear Benefits
Madan, R. A., Karzai, F., Vanderweele, D. J., Cheng, H. H. & De Bono, J. S., Dec 20 2023, In: Journal of Clinical Oncology. 41, 36, p. 5501-5504 4 p.Research output: Contribution to journal › Comment/debate › peer-review
3 Scopus citations -
Smart Nanocarriers for the Targeted Delivery of Therapeutic Nucleic Acid for Cancer Immunotherapy
Baker, A., Lorch, J., VanderWeele, D. & Zhang, B., Jun 2023, In: Pharmaceutics. 15, 6, 1743.Research output: Contribution to journal › Review article › peer-review
Open Access3 Scopus citations